MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer Clinical Trial

Official title:

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03585764
• Other study ID #: 830111 (UPCC-03818)
• Secondary ID: 1R01CA260902
• Status: Terminated
• Phase: Phase 1
• Start date: October 24, 2018
• Est. completion date: March 26, 2024

Study information

• Verified date: April 2024
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy

Description:

This is a Phase I study evaluating the safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design.

The DLT observation period is 28 days post CAR T cell infusion. The Maximum Tolerated Dose (MTD) is defined as the dose at which 0 or 1 DLT occurs in 6 evaluable subjects tested within the dose range of this study.

Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.

Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.

Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 46
• Est. completion date: March 26, 2024
• Est. primary completion date: March 26, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed persistent or recurrent stage II to IV high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Disease can be platinum-sensitive or platinum-resistant.

2. Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible.

3. Confirmation of tumor aFR expression (=70% of tumor cells with =2+ aFR staining).

4. Subjects must have measureable disease as defined by RECIST 1.1 criteria.

5. Patients with asymptomatic CNS metastases that have been treated and are off steroids are allowed. They must meet the following at the time of eligibility confirmation by physician-investigator:

1. No concurrent treatment for the CNS disease

2. No progression of CNS metastasis on brain MRI at screening

3. No evidence of leptomeningeal disease or cord compression

6. Patients = 18 years of age.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Satisfactory organ and bone marrow function as defined by the following:

i. Absolute neutrophil count = 1,000/µl ii. Platelets =75,000/µl iii. Hemoglobin = 9 g/dL iv. Total bilirubin = 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine = 1.5x the institutional normal upper limit vi. Albumin =2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 5x the institutional normal upper limit viii. Cardiac ejection fraction of =40%

9. Blood coagulation parameters: PT such that international normalized ratio (INR) is = 1.5 and a PTT = 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters.

10. Provides written informed consent.

11. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3.

Exclusion Criteria:

1. High grade serous ovarian, fallopian, or primary peritoneal cancer that is platinum refractory, defined as disease that has clinical or radiographic progression on platinum-based chemotherapy, as per the discretion of the treating physician.

2. Patients with symptomatic CNS metastases are excluded.

3. Participation in a therapeutic investigational study within 4 weeks prior to eligibility confirmation by physician-investigator, or anticipated treatment with another investigational product while on study. This refers to non-commercially approved investigational drugs different than those used in this protocol.

4. Active invasive cancer other than ovarian cancers. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder cancer) are not excluded.

5. HIV infection

6. Hepatitis B or hepatitis C infection

7. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to >/= 10 mg of prednisone. Patients with autoimmune neurologic diseases (such as multiple sclerosis) will be excluded.

8. Patients with active and uncontrolled infection.

9. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (<10 mg daily equivalent of prednisone). Corticosteroids treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional guidance. The use of topical and/or inhaled steroids are not exclusionary.

10. Patients requiring supplemental oxygen therapy.

11. Prior therapy with lentiviral gene modified cells.

12. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).

13. Any ascites requiring therapeutic drainage within 4 weeks prior to eligibility confirmation by physician-investigator.

14. Pregnant or breastfeeding women.

15. Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the physician-investigator, would make the patient inappropriate for entry into the study.

Related Conditions & MeSH terms

• Fallopian Tube Cancer
• Fallopian Tube Neoplasms
• Ovarian Cancer
• Primary Peritoneal Carcinoma

Intervention

Drug:
• MOv19-BBz CAR T cells
intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.

Device:
• Alpha Folate Receptor expression test
Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.

Locations

Country	Name	City	State
United States	University of Pennsylvania Health System	Philadelphia	Pennsylvania

Sponsors (5)

Lead Sponsor	Collaborator
University of Pennsylvania	Alliance for Cancer Gene Therapy, National Cancer Institute (NCI), OvaCure Fundation, Ovarian Cancer Alliance of Greater Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of study subjects with treatment-related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0		15 years
Secondary	Tumor response rates measured according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria		Day 28, Month 3, Month 6
Secondary	Progression-free survival (PFS)		5 years
Secondary	Overall response rates (ORR)		5 years
Secondary	Overall survival (OS)		15 years